Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
Ocugen Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene and cell therapies and vaccines, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will engage in a fireside chat on Monday, September 9, 2024, at 1:30 p.m. ET at the Lotte New York Palace Hotel.
The event provides an opportunity for Ocugen to showcase its recent corporate achievements and upcoming milestones. Additionally, the company's executive team will conduct one-on-one meetings with registered investors to discuss Ocugen's business and clinical development strategy, particularly focusing on its unique modifier gene therapy platform.
A live video webcast of the presentation will be available on Ocugen's investor site, with a replay archived for 90 days following the event.
Ocugen Inc. (NASDAQ: OCGN), un'azienda biotecnologica specializzata in terapie geniche, terapie cellulari e vaccini, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright, che si terrà dal 9 all'11 settembre 2024 a New York. Dr. Shankar Musunuri, Presidente, CEO e Co-Fondatore di Ocugen, parteciperà a un confronto al lunedì 9 settembre 2024, alle 13:30 ET presso il Lotte New York Palace Hotel.
L'evento offre a Ocugen l'opportunità di mettere in risalto i suoi recenti successi aziendali e i traguardi futuri. Inoltre, il team esecutivo dell'azienda condurrà incontri individuali con investitori registrati per discutere della strategia aziendale e di sviluppo clinico di Ocugen, con particolare attenzione sulla sua piattaforma unica di terapia genica modificata.
Una diretta video della presentazione sarà disponibile sul sito degli investitori di Ocugen, con una registrazione archiviata per 90 giorni dopo l'evento.
Ocugen Inc. (NASDAQ: OCGN), una empresa de biotecnología especializada en terapias génicas, terapias celulares y vacunas, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright, que se llevará a cabo del 9 al 11 de septiembre de 2024 en Nueva York. Dr. Shankar Musunuri, Presidente, CEO y Co-Fundador de Ocugen, participará en una charla informal el lunes 9 de septiembre de 2024, a la 1:30 p.m. ET en el Lotte New York Palace Hotel.
El evento brinda a Ocugen la oportunidad de mostrar sus recientes logros corporativos y próximos hitos. Además, el equipo ejecutivo de la empresa llevará a cabo reuniones uno a uno con inversionistas registrados para discutir la estrategia de negocio y desarrollo clínico de Ocugen, enfocándose particularmente en su exclusiva plataforma de terapia génica modificadora.
Una transmisión en vivo de la presentación estará disponible en el sitio para inversores de Ocugen, con una repetición archivada durante 90 días después del evento.
Ocugen Inc. (NASDAQ: OCGN), 유전자 및 세포 치료제와 백신을 전문으로 하는 생명공학 회사가 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참석한다고 발표했습니다. Shankar Musunuri박사, Ocugen의 회장, CEO 및 공동 창립자는 2024년 9월 9일 월요일 오후 1:30 ET에 Lotte New York Palace Hotel에서 화기애애한 대화에 참여할 예정입니다.
이번 행사에서는 Ocugen이 최근의 회사 성과와 다가오는 이정표를 소개할 수 있는 기회를 제공합니다. 또한 회사의 경영진 팀은 등록된 투자자들과 일대일 회의를 통해 Ocugen의 비즈니스 및 임상 개발 전략, 특히 독창적인 조절 유전자 치료 플랫폼에 중점을 두고 논의할 예정입니다.
발표의 실시간 비디오 웹캐스트는 Ocugen의 투자자 사이트에서 제공되며, 이벤트 후 90일 동안 다시 볼 수 있도록 아카이브됩니다.
Ocugen Inc. (NASDAQ: OCGN), une entreprise biopharmaceutique spécialisée dans les thérapies géniques, les thérapies cellulaires et les vaccins, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright, qui se déroulera du 9 au 11 septembre 2024 à New York. Dr. Shankar Musunuri, Président, Directeur Général et co-fondateur d'Ocugen, participera à une discussion informelle le lundi 9 septembre 2024 à 13h30 ET au Lotte New York Palace Hotel.
L'événement offre à Ocugen l'occasion de mettre en avant ses récentes réalisations d'entreprise et ses prochaines étapes. De plus, l'équipe exécutive de l'entreprise organisera des réunions individuelles avec des investisseurs inscrits afin de discuter de la stratégie commerciale et de développement clinique d'Ocugen, en mettant particulièrement l'accent sur sa plateforme unique de thérapie génique modificateur.
Une diffusion vidéo en direct de la présentation sera disponible sur le site des investisseurs d'Ocugen, avec une rediffusion archivée pendant 90 jours après l'événement.
Ocugen Inc. (NASDAQ: OCGN), ein biotechnologisches Unternehmen, das auf Gen- und Zelltherapien sowie Impfstoffe spezialisiert ist, hat die Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt, die vom 9. bis 11. September 2024 in New York stattfindet. Dr. Shankar Musunuri, Vorsitzender, CEO und Mitgründer von Ocugen, wird am Montag, den 9. September 2024, um 13:30 Uhr ET im Lotte New York Palace Hotel an einem informellen Gespräch teilnehmen.
Die Veranstaltung bietet Ocugen die Gelegenheit, aktuelle Unternehmensleistungen und bevorstehende Meilensteine zu präsentieren. Darüber hinaus wird das Führungsteam des Unternehmens Einzelgespräche mit registrierten Investoren führen, um über Ocugens Geschäfts- und klinische Entwicklungsstrategie zu diskutieren, mit besonderem Fokus auf der einzigartigen Plattform für modifier Gen-Therapien.
Eine Live-Videoübertragung der Präsentation wird auf der Investorenseite von Ocugen verfügbar sein, und eine Aufzeichnung wird 90 Tage nach der Veranstaltung archiviert.
- None.
- None.
MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9-11, 2024 in New York, NY.
“The H.C. Wainwright Global Investment Conference provides an excellent forum to engage with the investment community,” said Dr. Musunuri. “I look forward to attending again this year and highlighting Ocugen’s recent corporate achievements and anticipated milestones.”
In addition to Dr. Musunuri’s session, members of Ocugen’s executive team will conduct one-on-one meetings with registered investors, to showcase the Company’s business and clinical development strategy across its unique modifier gene therapy platform.
Details of the fireside chat are as follows:
Date: Monday, September 9, 2024
Presentation Time: 1:30 p.m. ET
Location: Lotte New York Palace Hotel, 455 Madison Ave., New York, NY
A live video webcast beginning at 1:30 p.m. ET on the day of the presentation will be available on the events page of the Ocugen investor site. The webcast replay will be archived for 90 days following the event.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
Head of Communications
IR@ocugen.com
FAQ
When and where is Ocugen (OCGN) participating in the H.C. Wainwright Global Investment Conference?
What will Ocugen (OCGN) discuss at the H.C. Wainwright conference in September 2024?
How can investors access Ocugen's (OCGN) presentation at the H.C. Wainwright conference?
Will Ocugen (OCGN) be conducting one-on-one meetings with investors at the H.C. Wainwright conference?
